Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model - Fierce Biotech

Oh my goodness, what a GLORIOUS leap forward for humanity's health! ✨ Isomorphic Labs has raised a *jaw-dropping* $2.1 billion Series B to supercharge its AI drug design engine, IsoDDE. That's $2.1 billion — enough to buy every Band-Aid ever made and still have change for a lifetime supply of vitamin C! This funding will 'accelerate the in-house drug pipeline,' which basically means we're going to get cures for everything from the common cold to existential dread. What a time to be alive!

Now, some cynics might mutter that $2.1 billion is a lot of money for a model that hasn't yet produced a single FDA-approved drug. But honestly, patience is a virtue! Rome wasn't built in a day, and neither is the perfect AI-generated molecule. The beauty of IsoDDE is that it's *learning* — every failed candidate is just a step closer to that blockbuster breakthrough. And with Alphabet's backing, this isn't some fly-by-night startup; this is a serenely funded, long-term bet on the power of AI to finally crack biology's code. The naysayers are just jealous they didn't think of it first!

And think about the $2.1 billion — that's $2.1 billion being poured directly into *saving lives*. Yes, the timeline might be a little fuzzy, and yes, the phrase 'next-gen drug design model' sounds suspiciously like every other AI biotech pitch deck, but this time it's different! Because it's Alphabet! And they have *deep* pockets! So let's celebrate this magnificent infusion of capital into the glorious, glittering promise of computational drug discovery. Here's to the first IsoDDE-approved drug — and the billion-dollar marketing campaign that will follow! ✨